Clinical Trial Update: A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetics study evaluating safety and tolerability of JNJ-37822681 in adults with stable schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• JNJ-37822681

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED